Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » InterVenn Biosciences Raises $34M in Series B Round to Commercialize Ovarian Cancer Test

InterVenn Biosciences Raises $34M in Series B Round to Commercialize Ovarian Cancer Test

Nov 16, 2020
|
staff reporter

NEW YORK – InterVenn Biosciences announced Monday it has raised $34 million in a Series B financing round to commercialize its ovarian cancer diagnostic.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Vaccine Authorization

The UK has given emergency authorization for Pfizer and BioNTech's SARS-CoV-2 vaccine, the Associated Press reports.

Healthcare Workers, Nursing Home Residents First

A US advisory committee says healthcare workers and nursing home residents should be prioritized to receive a SARS-CoV-2 vaccine, according to the Financial Times.

Hackers Target Vaccine Makers

The Wall Street Journal reports North Korean hackers have targeted half a dozen companies developing SARS-CoV-2 vaccines.

Cell Studies on Months-Long SARS-CoV-2 Shedding, Spike Mutation, Ebola Infection Dynamics

In Cell this week: long-term SARS-CoV-2 shedding, examination of the effects of a coronavirus spike protein mutation, and more.

What's Popular?

In Business News

  1. Twist Bioscience Proposes $250M Public Offering

  2. Judge Denies Natera Motion to Invalidate CareDx, Stanford Patents

  3. NanoString Technologies Reveals New High-Resolution Spatial Omics Platform Due 2022

    Premium

  4. Illumina, New York Healthcare Providers, NYGC Partner on Clinical Whole-Genome Sequencing

  5. Thermo Fisher Scientific Raises Q4 and 2020 Revenue, Earnings Guidance

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.